Antiemetic Prophylaxis with Fosaprepitant and 5-HT3-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Karin Melanie Cabanillas StanchiSemjon WillierJulia VekPatrick SchlegelManon QueudevilleNora RieflinVeronika KlausMelanie GanselJoachim Vincent RupprechtTim FlaadtVera BinderTobias FeuchtingerPeter LangRupert HandgretingerMichaela DöringPublished in: Drug design, development and therapy (2020)
The fosaprepitant-based antiemetic prophylaxis was safe, well tolerated and significantly reduced vomiting in children undergoing highly emetogenic chemotherapy prior to autoHSCT. Prospective randomized trials are necessary to confirm these results.